AbOliGo
AbOliGo is a startup company (founded 2024) developing a revolutionary platform for rapid production of antibody-oligonucleotide conjugates (AOCs), addressing a critical bottleneck in multiplexed protein analysis, proteomics and spatial biology. AOCs are transformative tools that combine antibodies' exquisite targeting specificity with oligonucleotides' unique properties - DNA amplification and molecular barcoding - enabling unlimited multiplexing. This fusion of genomics/transcriptomics capabilities with decades of antibody development has created powerful new research possibilities. However, while there are approximately 7 million commercially available antibodies, only ~0.03% are offered as oligo conjugates
Recognizing the growing demand for AOCs, we aim to innovate and re-imagine the manufacturing process through three key technological advancements, currently in development:
Scale - A novel conjugation methodology that enables production at µg scale.
Quality – Develop a QC quantitative release criteria, guaranteeing batch consistency.
Fast – manufacture and deliver AOCs from a large portfolio within 3 days.
Funding
Pre-seed - sufficient capital has been secured by the founders to launch AbOliGo and to support the initial R&D project.
Seed Funding – this round has started which we hope to close Summer 2025.
We are excited to be on this journey and are looking for highly energized investors to join – please contact us to learn more.